A panel of federal health experts unanimously rejected the use of Merck’s Proscar to prevent prostate cancer, saying the drug could actually raise the risk of the most serious types of tumors. Get the full story »
Inside these posts: Prostate-cancer treatment
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Oct. 26, 2010 at 5:15 p.m.
Comments Off
Filed under: Advertising/Marketing, Investigations, Pharmaceuticals U.S. states settle with Bayer over vitamin claims
Attorneys general in Illinois, Oregon and California said on Tuesday that Bayer AG agreed to a $3.3 million settlement over misleading claims that the drug maker’s vitamins reduced men’s risk of prostate cancer.
Under the terms of the settlement, Bayer cannot make claims that its One A Day Men’s multivitamins can prevent or cure prostate cancer or any other disease without scientific evidence, Illinois Attorney General Lisa Madigan said in a statement.
“When manufacturers like Bayer make marketing claims with insufficient scientific proof behind them, they are misleading consumers,” she said.
Get the full story »
Aug. 6, 2010 at 5:24 p.m.
Comments Off
Filed under: Advertising/Marketing, Government, Pharmaceuticals FDA orders halt to some Provenge marketing
The Food and Drug Administration has asked Dendreon Corp. to stop using some promotional materials for Provenge, saying they are “false or misleading” because they omit or minimize the prostate-cancer drug’s risks and overstate its effectiveness.
Provenge, which was approved by the agency in late April, is seen as the first in a new class of cancer-fighting drugs that use a patient’s cells to stimulate the body’s immune system to fight cancer. Get the full story »
